Key regions: United States, Europe, Brazil, Japan, United Kingdom
Bronchodilator drugs are used to treat respiratory diseases such as asthma, chronic obstructive pulmonary disease (COPD), and bronchitis. In Israel, the market for bronchodilator drugs has been witnessing steady growth in recent years.
Customer preferences: Patients in Israel prefer bronchodilator drugs that provide quick relief from respiratory symptoms. They also prefer drugs that have minimal side effects and are easy to use. As a result, there is a high demand for inhalers and nebulizers in the Israeli market.
Trends in the market: The Israeli bronchodilator drugs market is expected to grow in the coming years due to the increasing prevalence of respiratory diseases in the country. The aging population is also a key driver of the market, as older people are more susceptible to respiratory diseases. Additionally, the growing awareness about the benefits of early diagnosis and treatment of respiratory diseases is expected to boost the demand for bronchodilator drugs in Israel.
Local special circumstances: Israel has a well-developed healthcare system, which provides universal coverage to its citizens. The country has a high rate of healthcare expenditure, which is expected to further increase in the coming years. This is likely to drive the demand for bronchodilator drugs in the country, as patients will have greater access to healthcare services.
Underlying macroeconomic factors: Israel has a strong economy with a high GDP per capita. The country has a highly educated workforce and a thriving technology sector. These factors are expected to drive the growth of the bronchodilator drugs market in Israel, as patients will have greater purchasing power and access to advanced healthcare technologies. Additionally, the government has been investing heavily in the healthcare sector, which is expected to further boost the market for bronchodilator drugs in Israel.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
